Member Info for EmeraldCarrots

LOL!

Loads of news due.

Not on Illumina's one yet. This is what they are looking to get though. It is in Illumina's interests to help advertise Angle Plc's "dual analysis". One of Illumina’s assay panels (for lung cancer) has been produced to work with Angle's Parsortix system already as you can see now on Angle's site. They must be working on others for Breast cancer, Prostate cancer, lung cancer etc........... RNS's to follow no doubt when they are ready. The dual test can identify about ***TWICE*** the number of biomarkers a person's cancer has. Many modern cancer drugs lock on to biomarkers to deliver the cancer cell poison directly. Not only better but avoids most side effects of treatment.

==========================

Https://angleplc.com/laboratory-services/

================

From the above web page:-

Molecular analysis:

Next generation sequencing (NGS) dual analysis of CTC-DNA and cfDNA from a single blood tube. Two workflows, both using CTCs harvested using Parsortix technology:

Illumina’s cell-free DNA prep with enrichment and a custom 79-gene panel targeting lung cancer

ANGLE’s proprietary workflow using a 61 gene pan-cancer NGS panel with blocker displacement amplification

All IMHO.

Https://angleplc.com/laboratory-services/

==========================

Molecular analysis:

Next generation sequencing (NGS) dual analysis of CTC-DNA and cfDNA from a single blood tube. Two workflows, both using CTCs harvested using Parsortix technology:

Illumina’s cell-free DNA prep with enrichment and a custom 79-gene panel targeting lung cancer

ANGLE’s proprietary workflow using a 61 gene pan-cancer NGS panel with blocker displacement amplification

1981 / 16 - Analytical validation of ANGLE's combined IF and FISH assay for assessment of HER2 in circulating tumor cells

April 28, 2025, 9:00 AM - 12:00 PM.

American Association for Cancer Research;

2025 April 25-30; Chicago, IL.

=====================

Should be very interesting. This 9:00 AM - 12:00 PM, then the Artios one 2:00 pm – 5:00 pm CDT.

Anyone selling today or tomorrow must be completely insane. Broadmoor wannabe!!!

Genedrive® MT-RNR1

· Scottish Government announcement of £800k investment to support national phased implementation program of pharmacogenetic testing of MT-RNR1 in newborn babies in NHS Scotland using Genedrive's MT-RNR1 ID Kit

· NIHR and OLS Funding Package of c.£500k to address NICE Real World Evidence Generation Requirements for the Genedrive® MT-RNR1 ID Kit across 14 hospitals across the UK (PALOH-UK). Progressing as planned, with nine Group 1 sites live, -----***with a further five Group 2 sites phased to go-live from May 2025***-----.

Up 1.01%

they are buys, or a large yet undisclosed buy has happened. Fum eh!

Likely the FDA application will follow shortly after we get the CE mark confirmed.

The 332,226 @ 1.472 was a buy.

All IMHO.

Last day of April is next Wednesday. Still, if it's a few days later then no big deal.

From Half year report:-

· Market access routes and reimbursement strategies defined in key initial international target countries, including the Middle East region, with well-positioned and aligned in-country distributors, with required regulatory certification (CE-IVD under IVDR) on track for April 2025

Make that down 18%!

So why is the sp down 16%?

1981 / 16 - Analytical validation of ANGLE's combined IF and FISH assay for assessment of HER2 in circulating tumor cells

April 28, 2025, 9:00 AM - 12:00 PM.

American Association for Cancer Research;

2025 April 25-30; Chicago, IL.

=====================

Should be very interesting. This 9:00 AM - 12:00 PM, then the Artios one 2:00 pm – 5:00 pm CDT.

Details of the poster presentation on ART0380:

Abstract Title: Combination of the ATR inhibitor, ART0380, with irinotecan for treating ATM-negative tumors

Presenter: Helen M. R. Robinson, VP of Biology, Artios

Session: PO.ET06.02 – DNA Damage Response and Modulation of DNA Repair 1

Date Monday, April 28, 2025

Time: 2:00 pm – 5:00 pm CDT

Location: Section 16

The full poster abstract is available on the AACR Annual Meeting website.

===================================

https://www.artios.com/press-release/artios-pharma-announces-details-of-presentations-at-the-american-association-for-cancer-research-aacr-annual-meeting-2025/

Should be interesting.

Then appreciate Angle's dual analysis can detect about twice as many as with using CtDna analysis alone.........

The market is asleep to this.

- No wonder Illumina are working with Angle now................!

Then appreciate Angle's dual analysis can detect about twice as many as with using CtDna analysis alone.........

The market is asleep to this.

Is it not?

1. Has the "gold standard" circulating tumour cell (CTC) catching Parsortix system. Can catch live intact CTC's. No better sample to test possible. Other CTC catching systems either kill the samples, contaminate them so analysis can't be done or also catch far too many white cells at the same time making analysis difficult.

2. Existing clients include Astrazeneca and Eisai.

3. Also works closely with Illumina.

4. Working with illumina to offer CTC and CtDna "dual analysis" which means about twice as many biomarkers can be found.

5. Other clients include Artios Pharma, and Crescendo Biologics.

Current market cap only £30 Million.

All IMHO.

1. They need a way of getting the up to date HER2 status of breast cancer patients for Enhertu treatment.

2. They say they will have the fastest DNA evaluation with their new system. Think Angle's dual CTC/CtDna analysis to find biomarkers to target cancer. It seems the new system will be competing with Illumina.......

https://www.globenewswire.com/news-release/2025/02/20/3029971/0/en/Roche-unveils-a-new-class-of-next-generation-sequencing-with-its-novel-sequencing-by-expansion-technology.html

60p a share?

1. They need a way of getting the up to date HER2 status of breast cancer patients for Enhertu treatment.

2. They say they will have the fastest DNA evaluation with their new system. Think Angle's dual CTC/CtDna analysis to find biomarkers to target cancer. It seems the new system will be competing with Illumina.......

https://www.roche.com/media/releases/med-cor-2025-01-31#:~:text=The%20PATHWAY%20HER2%20(4B5)%20test,in%20breast%20cancer%20is%20evolving.

60p a share?

Status evaluation. They have the Roche test for evaluating the original removed tissue. All well and good for a start, apart from the HER2 status can change over time. Makes sense the next step will be to improve what they offer to include HER2 status eveluation shortly before treatment begins. If not the patient might not get the right treatment! The only way to do this at the moment is from a blood sample so it's right up Angle's street.